Genomtec (GMT) Q1 2025 earnings summary

Executive summary

• Genomtec S.A. focuses on R&D in molecular diagnostics, with flagship projects Genomtec ID and OncoSNAAT, aiming for commercialization via partnerships or licensing.

• The company is listed on the Warsaw Stock Exchange since February 2023 and does not yet generate significant product sales.

• In Q1 2025, Genomtec established two wholly-owned subsidiaries to manage key projects and completed a significant capital increase.

Financial highlights

• Q1 2025 revenue from sales: PLN 5,000, up from PLN 0 in Q1 2024; grant income: PLN 345,000, up from PLN 266,000.

• Operating loss: PLN -3,097,000 (Q1 2024: PLN -2,613,000); net loss: PLN -3,205,000 (Q1 2024: PLN -2,658,000).

• R&D expenses increased to PLN 1,097,000 from PLN 457,000 year-over-year.

• Cash and equivalents at period end: PLN 13,839,000 (Q1 2024: PLN 6,697,000); equity: PLN 15,171,000 (Q1 2024: PLN 7,600,000).

Outlook and guidance

• No significant product sales expected in the near term; revenue mainly from one-off customer orders and grants.

• Full commercialization and revenue growth depend on successful product launches and strategic partnerships in coming years.

• Continued access to grants and investor funding is critical for ongoing R&D and future commercialization.